Blood Screening Market Analysis

Blood Screening Market Analysis

To get key market trends

  Download Free Sample

The market by product is segmented into reagents & kits, and instruments. The reagents & kits segment is further divided into NAT reagents & kits, ELISA, and other reagents & kits. The reagents & kits segment accounted for majority revenue share and was valued at around USD 2.4 billion revenue in 2023.

• The growing focus on blood donation activities is a key driving factor for reagents and kits demand. As more people participate in blood donation programmes, there is a greater demand for screening reagents and kits to assure the safety and compatibility of donated blood.

   

• Moreover, automation and technology integration in blood screening procedures requires the use of specialised reagents and kits that are compatible with automated systems. Automation improves screening process efficiency, reduces mistakes, and boosts throughput, thereby, improving overall efficiency.

Based on technology, the blood screening market is categorized into nucleic acid test, serology/immunoassays, rapid test, western blot assays, and next generation sequencing. The nucleic acid test segment is further bifurcated into transcription-mediated amplification and real-time PCR. The serology/immunoassays segment in further divided into chemiluminescence immunoassay, fluorescent immunoassays, and colorimeter immunoassays/ELISA. The nucleic acid test segment dominated the market and accounted for over 43% business share in 2023 and is anticipated to witness significant growth during the forecast period.

• Nucleic acid tests offer higher sensitivity and specificity compared to traditional screening methods. Their ability to detect very low levels of viral or bacterial genetic material makes them crucial for early and accurate detection of infections, including HIV, hepatitis, and other transfusion-transmissible diseases.

   

• Additionally, NAT significantly reduces the window period compared to other screening methods, ensuring a shorter timeframe during which infections might go undetected, thereby contributing to the segmental growth. The window period refers to the time between start of infection and when the infection becomes detectable.
   

The blood screening market by end-use is categorized into hospitals, blood banks, and pathology laboratories. The blood banks segment accounted for over USD 1.7 billion revenue size in 2023.

• The increasing need for blood transfusions, which is being driven by an ageing population, medical procedures, surgeries, and the treatment of numerous medical problems such as cancer and anaemia, highlights the need for stringent blood screening in blood banks.

   

  Furthermore, blood banks conduct blood typing and compatibility testing to ensure the donated blood is compatible with the blood type of the recipient. The need to avoid adverse responses during transfusions drives the demand for reliable blood type and compatibility testing.

North America blood screening market accounted for USD 1.3 billion revenue in 2023 and is predicted to witness substantial market progression.

• The region experiences a consistently high demand for blood and blood products due to factors such as presence of considerable target population for different disorders, medical procedures, surgeries, trauma cases, and the prevalence of chronic diseases. The need for a secure and robust blood supply system fuels the adoption of advanced blood screening practices.

   

• Furthermore, North America is at the forefront of technological innovation in healthcare. The region witnesses continuous advancements in blood screening technologies, including nucleic acid testing (NAT), automated immunoassays, and state-of-the-art laboratory equipment. The adoption of such advanced mechanisms is driven by a commitment to providing cutting-edge healthcare solutions.